Correction to Lancet Oncol 2017; 18: e143–52 (The Lancet Oncology (2017) 18(3) (e143–e152), (S1470204517300748), (10.1016/S1470-2045(17)30074-8));iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

The Lancet Oncology

Volumn 18, Issue 3, 2017, Pages e143-e152

  Seymour, Lesley ^a   Bogaerts, Jan ^b   Perrone, Andrea ^c   Ford, Robert ^d   Schwartz, Lawrence H ^e,f   Mandrekar, Sumithra ^g   Lin, Nancy U ^h   Litière, Saskia ^b   Dancey, Janet ^a   Chen, Alice ⁱ   Hodi, F Stephen ^h   Therasse, Patrick ^j   Hoekstra, Otto S ^k   Shankar, Lalitha K ⁱ   Wolchok, Jedd D ^l   Ballinger, Marcus ^m,n,o   Caramella, Caroline ^p   de Vries, Elisabeth G E ^q  

^a QUEEN S UNIVERSITY   (Canada)

^b EORTC DATA CENTER   (Belgium)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Clinical Trials Imaging Consulting   (United States)

^e Department of Medicine   (United States)

^f NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^g MAYO CLINIC   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^k VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁿ LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^o GENENTECH INC   (United States)

^p INSTITUT GUSTAVE ROUSSY   (France)

^q UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SCREENING; HUMAN; IMMUNOMODULATION; LUNG CANCER; MELANOMA; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; REVIEW; SOLID TUMOR; TUMOR VOLUME; DISEASE COURSE; IMMUNOTHERAPY; NEOPLASMS; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; STANDARDS;

DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; TUMOR BURDEN;

EID: 85014322386     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(19)30240-2     Document Type: Erratum

References (35)

1. 1 Kim, C, Prasad, V, Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern Med 175 (2015), 1992–1994.
2. 2 Miller, AB, Hoogstraten, B, Staquet, M, Winkler, A, Reporting results of cancer treatment. Cancer 47 (1981), 207–214.
3. 3 Therasse, P, Arbuck, SG, Eisenhauer, EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000), 205–216.
4. 4 Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1·1). Eur J Cancer 45 (2009), 228–247.
5. 5 Liu, Y, Litière, S, de Vries, EG, et al. The role of response evaluation criteria in solid tumor in anticancer treatment evaluation: results of a survey in the oncology community. Eur J Cancer 50 (2014), 260–266.
6. 6 Schwartz, LH, Seymour, L, Litière, S, et al. RECIST 1.1—standardisation and disease-specific adaptations: perspectives from the RECIST working group. Eur J Cancer 62 (2016), 138–145.
7. 7 Schwartz, LH, Litière, S, de Vries, E, et al. RECIST 1·1—update and clarification: from the RECIST committee. Eur J Cancer 62 (2016), 132–137.
8. 8 Brahmer, J, Reckamp, KL, Baas, P, Crinò, L, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373 (2015), 123–135.
9. 9 Pardoll, Drew M, The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 (2012), 252–264.
10. 10 Sidaway, P, Bladder cancer: atezolizumab effective against advanced-stage disease. Nat Rev Urol, 13, 2016, 238.
11. 11 Holt, GE, Podack, ER, Raez, LE, Immunotherapy as a strategy for the treatment of non-small cell lung cancer. Therapy 8 (2011), 43–54.
12. 12 Sharma, P, Wagner, K, Wolchok, JD, Allison, JP, Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 11 (2011), 805–812.
13. 13 Antonia, S, Goldberg, SB, Balmanoukian, A, et al. Safety and antitumor activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 3 (2016), 299–308.
14. 14 Postow, MA, Chesney, J, Pavlick, AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372 (2015), 2006–2017.
15. 15 Reck, M, Bondarenko, I, Luft, A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 24 (2013), 75–83.
16. 16 Lynch, TJ, Bondarenko, I, Luft, A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small cell lung cancer: results from a randomized, double-blind, multi-center phase II study. J Clin Oncol 30 (2012), 2046–2054.
17. 17 Larkin, J, Chiarion-Sileni, V, Gonzalez, R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.
18. 18 Hodi, FS, O'Day, SJ, McDermott, DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
19. 19 Topalian, SL, Hodi, FS, Brahmer, JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Eng J Med 366 (2012), 2443–2454.
20. 20 Borghaei, H, Paz-Ares, L, Horn, L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
21. 21 Garon, EB, Rizvi, N, Hui, R, et al. Pembrolizumab for the treatment of non-small cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
22. 22 Rosenberg, JE, Hoffman-Censits, J, Powles, T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387 (2016), 1909–1920.
23. 23 Motzer, RJ, Escudier, B, McDermott, DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
24. 24 Fife, BT, Bluestone, JA, Control of peripheral T-cell tolerance and autoimmunity via CTLA-4 and PD-1 pathways. Immunol Rev 224 (2008), 166–182.
25. 25 Fife, BT, Pauken, KE, Eagar, TN, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 10 (2009), 1185–1192.
26. 26 Iwai, Y, Ishida, M, Tanaka, Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99 (2002), 12293–12297.
27. 27 Tarhini, AA, Tremelimumab: a review of development to date in solid tumors. Immunotherapy 5 (2013), 215–229.
28. 28 Hoos, A, Parmiani, G, Hege, K, et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 30 (2007), 1–15.
29. 29 Wolchok, JD, Hoos, A, O'Day, S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15 (2009), 7412–7420.
30. 30 Nishino, M, Giobbie-Hurder, A, Gargano, M, Suda, M, Ramaiya, NH, Hodi, FS, Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res 19 (2013), 3936–3943.
31. 31 Bohnsack, O, Ludajic, K, Hoos, A, Adaptation of the immune-related response criteria: irRECIST. Ann Oncol 25:suppl 4 (2014), iv361–iv372.
32. 32 Hodi, FS, Hwu, WJ, Kefford, R, et al. Evaluation of immune-related response criteria and RECIST v1·1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 34 (2016), 1510–1517.
33. 33 Chiou, VL, Burotto, M, Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33 (2015), 3541–3543.
34. 34 Kurra, V, Sullivan, RJ, Gainor, JF, et al. Pseudoprogression in cancer immunotherapy: rates, time course and patient outcomes. Proc Am Soc Clin Oncol, 34, 2016 abstr 6580.
35. 35 Reck, M, Rodríguez-Abreu, D, Robinson, AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med 375 (2016), 1823–1833.